15-OR: Renal Outcomes from the DECLARE-TIMI 58 Trial: Quantifying the Health-Care Implications

Chronic kidney disease (CKD) and end stage renal disease (ESRD) pose a significant global health burden. Approximately 40% of people with type 2 diabetes develop CKD. The Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 trial showed a reduced rate of the composite endpoint of sustaine...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Diabetes (New York, N.Y.) N.Y.), 2019-06, Vol.68 (Supplement_1)
Hauptverfasser:	MCEWAN, PHILIP, KARTMAN, BERNT, BENNETT, HAYLEY, EDMONDS, CHRISTOPHER, GAUSE-NILSSON, INGRID ANNA
Format:	Artikel
Sprache:	eng
Schlagworte:	Diabetes Diabetes mellitus Diabetes mellitus (non-insulin dependent) Dialysis Epidermal growth factor receptors Glomerular filtration rate Kidney diseases Quality of life
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!